Sartorius Stedim Biotech SA
PAR:DIM

Watchlist Manager
Sartorius Stedim Biotech SA Logo
Sartorius Stedim Biotech SA
PAR:DIM
Watchlist
Price: 175 EUR 3.8% Market Closed
Market Cap: 17B EUR
Have any thoughts about
Sartorius Stedim Biotech SA?
Write Note

Sartorius Stedim Biotech SA
Long-Term Investments

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Sartorius Stedim Biotech SA
Long-Term Investments Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Investments CAGR 3Y CAGR 5Y CAGR 10Y
Sartorius Stedim Biotech SA
PAR:DIM
Long-Term Investments
€36.7m
CAGR 3-Years
35%
CAGR 5-Years
44%
CAGR 10-Years
38%
Pcas SA
PAR:PCA
Long-Term Investments
€117k
CAGR 3-Years
2%
CAGR 5-Years
-17%
CAGR 10-Years
-16%
Eurofins-Cerep SA
PAR:ALECR
Long-Term Investments
€17k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-32%
No Stocks Found

Sartorius Stedim Biotech SA
Glance View

Market Cap
17B EUR
Industry
Life Sciences Tools & Services

Sartorius Stedim Biotech SA, a key player in the biopharmaceutical industry, has positioned itself at the forefront of innovation in bioprocessing and laboratory solutions. Established in the early 2000s through the merger of Sartorius AG's biotech division and Stedim S.A., the company’s mission centers on enabling the development and production of life-saving biologics. With a comprehensive portfolio that includes bioprocessing equipment, research services, and laboratory instruments, Sartorius caters to a vast array of customers, from small biotech firms to large pharmaceuticals, ensuring seamless workflows in drug development and manufacturing. By leveraging cutting-edge technologies and maintaining a commitment to sustainability, Sartorius has built a reputation as a trusted partner in the industry, addressing the growing demand for effective therapies amidst an ever-evolving healthcare landscape. As the global biopharmaceutical market expands, driven by advancements in personalized medicine and precision therapies, Sartorius is well-positioned to capitalize on these trends. The company’s recent strategic acquisitions and investments in digitalization and automation enhance its product offerings, allowing clients to improve efficiencies and reduce time-to-market for essential therapeutics. Boasting a strong financial track record and a commitment to research and development, Sartorius Stedim Biotech SA not only ensures consistent growth but also aligns with long-term health sector trends. For investors, this combination of strategic vision, robust market position, and innovative capabilities makes Sartorius an attractive investment opportunity in the booming biotechnology sector.

DIM Intrinsic Value
159.09 EUR
Overvaluation 9%
Intrinsic Value
Price

See Also

What is Sartorius Stedim Biotech SA's Long-Term Investments?
Long-Term Investments
36.7m EUR

Based on the financial report for Jun 30, 2024, Sartorius Stedim Biotech SA's Long-Term Investments amounts to 36.7m EUR.

What is Sartorius Stedim Biotech SA's Long-Term Investments growth rate?
Long-Term Investments CAGR 10Y
38%

Over the last year, the Long-Term Investments growth was 50%. The average annual Long-Term Investments growth rates for Sartorius Stedim Biotech SA have been 35% over the past three years , 44% over the past five years , and 38% over the past ten years .

Back to Top